Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 56,409	$ 84,833
Prepaid expenses and other current assets	3,109	3,513
Total current assets	59,518	88,346
Operating lease asset, net	739	768
Goodwill	0	48,648
In-process research and development	32,386	32,386
Other assets	150	400
Total assets	92,793	170,548
Current liabilities:
Accounts payable	2,200	1,813
Current operating lease liability	363	369
Accrued expenses and other liabilities	3,912	2,219
Total current liabilities	6,475	4,401
Deferred tax liability	1,752	1,752
Non-current operating lease liability	383	400
Total liabilities	8,610	6,553
Commitments and contingencies (Note 6)
Stockholders’ equity:
Common stock, $0.001 par value, 200,000,000 shares authorized at December 31, 2022 and 2021; 13,776,788 and 14,306,788 shares issued and outstanding at December 31, 2022 and 2021, respectively	14	14
Additional paid-in capital	287,034	278,880
Accumulated deficit	(202,865)	(114,899)
Total stockholders’ equity	84,183	163,995
Total liabilities and stockholders’ equity	92,793	170,548
Series X1 Non-voting Convertible Preferred Stock [Member]
Stockholders’ equity:
Preferred stock, value
Series X Non-voting Convertible Preferred Stock [Member]
Stockholders’ equity:
Preferred stock, value

In-process research and development.

No definition available.

Name:	eldn_InProcessResearchAndDevelopment
Namespace Prefix:	eldn_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).